reports
uniQure Announces First Quarter 2024 Financial Results and Highlights ...
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress ~ On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical update from the Phase I/II trials in mid-2024 ~ ~ Clinical trial initiation for Fabry disease on track to begin in second quarter of 2024, followed by refractory mesial temporal lobe epilepsy and SOD1-ALS in third quarter of 2024 ~ ~ Comprehensive review of operations and options to reduce expenses underway and expected to be completed in mid-2024 ~ LEXINGTON, Mass. and AMSTERDAM, May 07, 2...
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® (pegcetacoplan injection) $25.6 million for EMPAVELI® (pegcetacoplan) Anticipates CHMP opinion for pegcetacoplan in GA no later than July 2024On track to report topline Phase 3 data with systemic pegcetacoplan in C3G / IC-MPGN in mid-2024Cash and cash equivalents of $325.9 million as of March 31, 2024; projected revenues and cash expected to be sufficient to fund operations for foreseeable futureMan...
Eledon Announces Clinical Progress with Tegoprubart in the Prevention ...
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Company reports updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the first participant in an investigator-led clinical ...
The Joint Corp. to Participate in Upcoming Investor Conferences
The Joint Corp. to Participate in Upcoming Investor Conferences SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation’s largest provider of chiropractic care through The Joint Chiropractic® network, announced that President and Chief Executive Officer Peter Holt and Chief Financial Officer Jake Singleton are scheduled to participate in the following upcoming conferences: 24th Annual B. Riley Institutional Investor Conference in Beverly Hills, CA Thursday, May 23Roundtable conversation at 1:45 pm PTOne-on-one meetings all day Oppenhei...
SES’s O3b mPOWER System Launches Service via Gilat’s SkyEdge IV Platfo...
SES’s O3b mPOWER System Launches Service via Gilat’s SkyEdge IV Platform SkyEdge IV – the industry’s first MEO-GEO system – enables O3b mPOWER software-driven constellation to deliver services with unparalleled flexibility and scale PETAH TIKVA, Israel, May 07, 2024 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today that its SkyEdge IV platform is enabling SES’s O3b mPOWER System to deliver high-performance connectivity services. SkyEdge IV is Gilat’s next-generat...
Prelude Therapeutics Reports First Quarter 2024 Financial Results and ...
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 New preclinical data presented at AACR 2024 included first characterization of PRT7732, a highly-selective, orally bioavailable SMARCA2 degrader Operational leadership capabilities further strengthened by recent hires Chief Business Officer Sean Brusky and Senior Vice President, Investor Relations Robert Doody Current cash runway ...
First Watch Restaurant Group, Inc. Reports Strong Q1 2024 Financial Re...
First Watch Restaurant Group, Inc. Reports Strong Q1 2024 Financial Results Total revenues increased 14.7%; same-restaurant sales growth of 0.5%*Income from operations margin of 5.1% and restaurant level operating profit margin of 20.8%Net income of $7.2 million and Adjusted EBITDA of $28.6 million9 system-wide restaurants opened across 8 states BRADENTON, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today reported financial results for...
BioCryst to Present at Upcoming Investor Conferences
BioCryst to Present at Upcoming Investor Conferences RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will present at the following conferences: Citizens JMP Life Sciences Conference in New York on Monday, May 13, 2024, at 12:30 p.m. ET. 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 2024, at 3:05 p.m. ET. Bank of America Health Care Conference 2024 in Las Vegas on Wednesday, May 15, 2024, at 5:20 p.m. ET. H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York on Monday...
Meritage Homes Announces Pricing of Convertible Senior Notes
Meritage Homes Announces Pricing of Convertible Senior Notes SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Meritage Homes Corporation (NYSE: MTH, “Meritage” or the “Company”), the fifth-largest homebuilder in the U.S., today announced the pricing of $500 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2028 (the “notes”). The Company also granted the initial purchasers of the notes a 13-day option to purchase up to $75 million of aggregate principal amount of additional notes. The sale of the notes is expected to settle on May 9, 2024, subject to customar...
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024 Eight presentations showcase the broad applicability of HSC gene therapy to address rare neurometabolic diseases and beyond TOKYO, LONDON and BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced four oral and four poster presentations from across its hematopoietic stem cell (HSC) gene therapy platform will be featured at the 27th Annual Meeting of the American Society ...
Arvinas Reports First Quarter 2024 Financial Results and Provides Corp...
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update – Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for up to $1.01 ...
Scholar Rock Reports First Quarter 2024 Financial Results and Highligh...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the first quarter ended March 31, 2024. “Scholar Rock is now only two quarters away from reporting topline data for our pivotal Phase 3 SAPPHIRE trial, which has the potential to build upon the promising data generated from our prior Phase 2 trial,”...
RAPPEL -- Assemblée annuelle et extraordinaire des actionnaires et tél...
RAPPEL -- Assemblée annuelle et extraordinaire des actionnaires et téléconférence du premier trimestre de Stella-Jones MONTRÉAL, 07 mai 2024 (GLOBE NEWSWIRE) -- L’assemblée annuelle et extraordinaire des actionnaires de Stella-Jones Inc. aura lieu en format hybride : Mercredi le 8 mai 2024 à 10h00 (Heure avancée de l’Est) En personne :1250 boulevard René-Lévesque Ouest, bureau 3610 Montréal, QuébecOu virtuellement par webdiffusion :Mot de passe : stella2024 (Le mot de passe est sensible à la casse) Les membres de la direction seront disponibles pour rencontrer les journalistes immédiat...
Akoustis to Webcast Q3FY24 Results on May 13 at 8:00 am ET
Akoustis to Webcast Q3FY24 Results on May 13 at 8:00 am ET Charlotte, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, will webcast its Q3FY24 results on Monday, May 13, 2024, at 8:00 am Eastern Time. Management will host a question-and-answer session at the end of the call. To listen to the call by telephone, please dial 877-407-3982 (domestic) or 201-493-6780 (international). The con...
Theriva™ Biologics Reports First Quarter 2024 Operational Highlights a...
Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results - Reported topline data from the investigator sponsored Phase 1 trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma; trial results were determined to be positive by the study Monitoring Committee- -Presented preclinical data demonstrating the potential synergy between VCN-01 and liposomal irinotecan in a human pancreatic mouse xenograft at the ASGCT Annual Meeting; emphasizes VCN-01’s potential in diverse chemotherapy combinations for improved efficacy in pancreatic canc...
InspireMD to Report First Quarter 2024 Financial Results and Provide C...
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th -Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2024 financial results on Tuesday, May 14th, before the financial markets open. Management will host a conference call and webcast with the i...
Blade Air Mobility Reports Financial Results for the First Quarter End...
Blade Air Mobility Reports Financial Results for the First Quarter Ended March 31, 2024 Achieved record-high Medical revenue of $36.0 million in Q1 2024, a 34.6% increase versus the prior year period and a 12.6% sequential increase versus Q4 2023.Net loss improved by $6.0 million versus the prior year to $(4.2) million in Q1 2024; Adjusted EBITDA improved by $4.2 million versus the prior year to $(3.5) million in Q1 2024.Record-high Medical Segment Adjusted EBITDA of $4.4 million in Q1 2024, up 134.5%, while Passenger Segment Adjusted EBITDA improved by $0.4 million, versus the prior year p...
IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Confere...
IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the 2024 RBCCM Global Healthcare Conference on Tuesday, May 14, 2024, at 2:35 p.m. EDT. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at . A replay of the webcast will be a...
Solid Biosciences to Present at the American Society of Gene and Cell ...
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting — Presentations to highlight AAV manufacturing and purification improvements, vector biology updates,and a comprehensive non-clinical data overview of the company’s lead SGT-003 program — CHARLESTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present an oral presentation and six posters and at the American Society of Gene and Cell Therapy (ASGCT) 2024 ...
XPO Opens New Service Center in Las Vegas to Expand Trade Show Shippin...
XPO Opens New Service Center in Las Vegas to Expand Trade Show Shipping and Strengthen Freight Transportation Across the Region XPO’s Second Location in Las Vegas Joins Recently Opened Facilities in Rapidly Growing Freight Markets GREENWICH, Conn., May 07, 2024 (GLOBE NEWSWIRE) -- (NYSE: XPO), a leading provider of LTL freight transportation in North America, today announced the opening of a major new freight transportation center in Las Vegas that will serve as a linchpin for the company’s expanded . The new site, XPO’s second in Las Vegas, also enables faster service to local custom...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.